The chronic disease is unpredictable and often has subtle symptoms that are easily missed or attributed to other ailments.

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

It is remarkable that something as small as the acidity of a tiny organelle within a cell could make such a big difference." Jonathan Miner, MD, PhD, Associate Professor of Rheumatology and ...